Foundation Medicine’s Next-Generation Sequencing Data to be Presented at 103rd AACR Annual Meeting 2012
News Mar 28, 2012
Foundation Medicine, Inc. announced that new data highlighting the company’s next-generation sequencing approach in clinical oncology will be presented at the 103rd American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31 through April 4 in Chicago.
The presentations will highlight the technical feasibility and clinical relevance of the company’s next-generation sequencing platform for oncology, which offers a fully informative genomic profile of the relevant alterations present in about 200 genes known to be somatically altered in human cancers. In these studies, the profile demonstrated concordance with existing commercial offerings and identified all classes of genomic alterations. In one study being presented, approximately 70 percent of cases were found to carry one or more actionable alterations, meaning the alteration could plausibly confer sensitivity or resistance to approved or experimental targeted therapies. The studies also identified more classes of alterations, including base pair mutations, insertions and deletions, copy number alterations and select gene fusions and rearrangements, than other commercially available molecular diagnostic tests.
“The data presented at AACR show that the breadth and relevance of Foundation Medicine’s genomic profile may offer important information for cancer treatment decisions, while fitting easily into routine clinical practice,” said Vincent Miller, M.D., senior vice president, clinical development, Foundation Medicine. “These findings support the feasibility of our fundamental mission to help practicing oncologists integrate the unique molecular information for each patient’s tumor into clinical decision making.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE